Skip to main content

Table 1 Results of univariable analyses on demographic, clinical and psychosocial baseline variables

From: Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment

  No use of psychosocial support services (n = 279)(n,%) Use of psychosocial support services (n = 70)(n,%) p-value
Age, years    *0.003
Mean age (SD) 66.92 (9.7) 62.74 (11.41)  
Gender    0.415
 Male 182 (65.2) 42 (60.0)  
 Female 97 (34.8) 28 (40.0)
Treatment arm in TES trial    0.610
 Intervention 149 (53.4) 35 (50)  
 Control 130 (46.6) 35 (50)
ECOG PSa    0.714
 0 67 (24.0) 15 (21.4)  
 1 87 (31.2) 18 (25.7)
 2 8 (2.9) 3 (4.3)
 Missing 117 (41.9) 34 (48.6)
Primary tumor location    0.695
 Right-sided 84 (30.1) 23 (32.9)  
 Left-sided 192 (68.8) 47 (67.1)
 Missing 3 (1.1)
Chemotherapy regimen    0.875
 Capecitabine 59 (21.1) 13 (18.6)  
 CAPOX 190 (68.1) 50 (71.4)
 FOLFOX/Other 27 (9.7) 7 (10.0)
 Missing 3 (1.1)
Number of comorbidities    0.980
 Mean (SD) 2.33 (1.78) 2.33 (2.00)  
Marital status    0.369
 Married/domestic partnership 207 (74.2) 49 (70.0)  
 Unmarried/divorced/widowed 68 (24.4) 21 (30.0)
 Missing 4 (1.4)
Number of persons in household    0.615
 1 49 (17.6) 13 (18.6)  
 2 177 (63.4) 42 (60.0)
 3 23 (8.2) 4 (5.7)
  > 3 26 (9.3) 11 (15.7)
 Missing 4 (1.4)
Educationb    *0.041
 Low 17 (6.1) 2 (2.9)  
 Middle 184 (65.9) 39 (55.7)
 High 72 (25.8) 29 (41.4)
 Missing 6 (2.2) 0 (0)
Currently working    0.949
 Yes 65 (23.3) 16 (22.9)  
 No/retired 210 (75.3) 54 (77.1)
 Missing 4 (1.4)
Time from diagnosis primary tumor until start study    0.848
  < 1.5 months 94 (33.7) 22 (31.4)  
 1.5–10 months 89 (31.9) 25 (35.7)
  > 10 months 93 (33.3) 23 (32.9)
 Missing 3 (1.1)
Time from diagnosis metastatic disease until start study    0.666
  < 1.0 months 95 (34.1) 27 (38.6)  
 1.0–2.5 months 87 (31.2) 23 (32.9)
  > 2.5 months 94 (33.7) 20 (28.6)
 Missing 3 (1.1)
Prior cancer related treatment
 No 85 (30.5) 23 (32.9) 0.699
 Yes 194 (69.5 47 (67.1)
Prior treatment metastases
 No 214 (76.7) 56 (80.0) 0.657
 Yes 62 (22.2) 14 (20.0)
 Missing 3 (1.1)
Number of organs with metastases    0.599
 Median 2 2  
Total number of metastases
 Median 11.5 13.0 0.877
Participation in other trials    0.718
 No 170 (60.9) 41 (58.6)  
 Yes 109 (39.1) 29 (41.4)
HADS
 Total score 9.10 (6.30) 11.17 (7.47) *0.020
 Distress on HADS No 208 (74.6) 44 (62.9) *0.033
  Yes 67 (24.0) 26 (37.1)  
  Missing 4 (1.4)
DT/PL
 DT score 4.33 (2.68) 4.75 (2.40) *0.242
 Total of physical problems 5.78 (6.29) 7.37 (4.61) *0.020
 Total of emotional problems 1.95 (2.11) 2.74 (2.57) *0.009
 Need to talk to professional No 257 (92.1) 58 (82.9) *0.023
  Yes 22 (7.9) 12 (17.1)  
Quality of life (QLQ-C30)
 Physical functioning 74.84 (20.30) 72.76 (21.88) 0.451
 Role functioning 65.69 (30.70) 58.81 (30.13) *0.010
 Emotional functioning 78.25 (18.12) 72.86 (21.41) *0.095
 Cognitive functioning 89.44 (14.97) 86.90 (16.76) *0.219
 Social functioning 78.08 (23.89) 69.05 (31.38) *0.010
 Global QOL 63.77 (21.73) 60.00 (21.78) *0.197
 Pain score 16.00 (23.75) 40.15 (26.57) *0.174
 Fatigue score 25.00 (16.67) 45.08 (44.44) *0.009
  1. Abbreviations: SD standard deviation, ECOG PS Eastern Cooperative Oncology Group Performance Status, HADS Hospital Anxiety and Depression Scale, DT/PL Distress Thermometer and Problem list, QLQ-C30 Quality of Life Questionnaire-C30. *Characteristics were included in the multivariate model if they had an univariable association (p ≤ .25). aECOG PS 0: Fully active, able to carry on all pre-disease performance without restriction. ECOG PS 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. ECOG PS 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. bLow: primary education, middle: lower general secondary education, intermediate vocational education or high school, high: higher vocational education or university